Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 5
2007 2
2008 1
2009 2
2010 1
2011 1
2012 2
2013 1
2014 2
2015 4
2016 3
2017 1
2018 3
2019 2
2020 2
2021 2
2022 1
2024 3
2025 2
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Etanercept and uveitis in patients with juvenile idiopathic arthritis.
Schmeling H, Horneff G. Schmeling H, et al. Rheumatology (Oxford). 2005 Aug;44(8):1008-11. doi: 10.1093/rheumatology/keh658. Epub 2005 Apr 26. Rheumatology (Oxford). 2005. PMID: 15855187
CONCLUSION: During treatment with etanercept, there were both relapses and first courses of uveitis. In addition, the frequency and severity of uveitis seemed not to be influenced by etanercept. In particular, patients with relapsing uveitis bef …
CONCLUSION: During treatment with etanercept, there were both relapses and first courses of uveitis. In addition, the frequenc …
Uveitis Is a Risk Factor for Juvenile Idiopathic Arthritis' Significant Flare in Patients Treated With Biologics.
Kostik MM, Gaidar EV, Sorokina LS, Avrusin IS, Nikitina TN, Isupova EA, Chikova IA, Korin YY, Orlova ED, Snegireva LS, Masalova VV, Dubko MF, Kalashnikova OV, Chasnyk VG. Kostik MM, et al. Front Pediatr. 2022 Jun 15;10:849940. doi: 10.3389/fped.2022.849940. eCollection 2022. Front Pediatr. 2022. PMID: 35783325 Free PMC article.
The presence of uveitis increased the risk of JIA flare, OR = 3.8 (95% CI: 1.7; 8.7), and the cumulative probability of joint flare, RR = 4.5 (95% CI: 1.7; 12.1), p =.003, after adjustment on methotrexate, RR = 3.1 (1.6; 6.), p =.0008. In the subgroup of pati …
The presence of uveitis increased the risk of JIA flare, OR = 3.8 (95% CI: 1.7; 8.7), and the cumulative probability of joint …
Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Tynjälä P, et al. Ann Rheum Dis. 2007 Apr;66(4):548-50. doi: 10.1136/ard.2006.058248. Epub 2006 Oct 26. Ann Rheum Dis. 2007. PMID: 17068061 Free PMC article.
OBJECTIVE: To evaluate the efficacy of anti-tumour necrosis factor (anti-TNF) treatment in juvenile idiopathic arthritis (JIA)-associated uveitis. METHODS: 24 patients with uveitis taking etanercept and 21 taking infliximab were studied. ...Inflammatory activ …
OBJECTIVE: To evaluate the efficacy of anti-tumour necrosis factor (anti-TNF) treatment in juvenile idiopathic arthritis (JIA)-associated …
Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication.
Aquilani A, Marafon DP, Marasco E, Nicolai R, Messia V, Perfetti F, Magni-Manzoni S, De Benedetti F. Aquilani A, et al. J Rheumatol. 2018 Jul;45(7):956-961. doi: 10.3899/jrheum.170794. Epub 2018 May 1. J Rheumatol. 2018. PMID: 29717035
OBJECTIVE: To evaluate the rate of flare after etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA) who attained clinical remission while taking medication, and to identify predictors of flare. ...Demographic and clinical features …
OBJECTIVE: To evaluate the rate of flare after etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA …
Uveitis as predictor of disease flare after the first anti-TNF withdrawal in oligoarticular and polyarticular juvenile idiopathic arthritis: a multicentric Italian experience.
Maccora I, Accardo V, Cattalini M, Pagnini I, Taddio A, Marrani E, La Torre F, Mastrolia MV, Bellicini I, Pastore S, Simonini G. Maccora I, et al. Clin Exp Rheumatol. 2024 Sep;42(9):1867-1875. doi: 10.55563/clinexprheumatol/3mxsll. Epub 2024 Jul 4. Clin Exp Rheumatol. 2024. PMID: 38976296 Free article.
We aim to describe a multicentric cohort of JIA treated with adalimumab or etanercept who discontinued the treatment for persistent inactivity and to identify factors associated with relapse. ...Patients with uveitis relapsed earlier (log rank chi2 16.4 p<0.0001) …
We aim to describe a multicentric cohort of JIA treated with adalimumab or etanercept who discontinued the treatment for persistent i …
Screening for juvenile idiopathic arthritis associated uveitis with laser flare photometry in the pediatric rheumatology office: a prospective observational study.
Ede K, Shishov M, Wershba E, Goswami N, Gorry S, Joseph M, Mirea L, O'Neil J. Ede K, et al. Pediatr Rheumatol Online J. 2024 Jan 26;22(1):22. doi: 10.1186/s12969-024-00961-9. Pediatr Rheumatol Online J. 2024. PMID: 38279120 Free PMC article.
The purpose of this study was to evaluate laser flare photometry (LFP) use to diagnose JIA-U in the Pediatric Rheumatology clinic for patients with JIA. ...At enrollment, 16 patients (27.6%) were not on medications, with 20 (34.5%) on methotrexate, 20 (34.5%) on adalimumab …
The purpose of this study was to evaluate laser flare photometry (LFP) use to diagnose JIA-U in the Pediatric Rheumatology clinic for …
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
Braun J, Baraliakos X, Listing J, Sieper J. Braun J, et al. Arthritis Rheum. 2005 Aug;52(8):2447-51. doi: 10.1002/art.21197. Arthritis Rheum. 2005. PMID: 16052578 Review.
METHODS: Data from 4 placebo-controlled studies with anti-TNF agents in AS (2 with etanercept and 2 with infliximab) and 3 open-label studies were analyzed for the prestudy prevalence and the incidence of reported flares of anterior uveitis. ...Flares …
METHODS: Data from 4 placebo-controlled studies with anti-TNF agents in AS (2 with etanercept and 2 with infliximab) and 3 open-label …
Childhood sarcoidosis: Louisiana experience.
Gedalia A, Khan TA, Shetty AK, Dimitriades VR, Espinoza LR. Gedalia A, et al. Clin Rheumatol. 2016 Jul;35(7):1879-84. doi: 10.1007/s10067-015-2870-9. Epub 2015 Jan 24. Clin Rheumatol. 2016. PMID: 25616361
Other immunomodulators included cyclophosphamide (2 patients), etanercept (2), infliximab (2), mycophenolate mofetil (1), and tacrolimus (1). Childhood sarcoidosis is prevalent in Louisiana. ...Early-onset disease is less common and associated with increased morbidity, …
Other immunomodulators included cyclophosphamide (2 patients), etanercept (2), infliximab (2), mycophenolate mofetil (1), and tacroli …
Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials.
Roche D, Badard M, Boyer L, Lafforgue P, Pham T. Roche D, et al. Arthritis Res Ther. 2021 Jul 16;23(1):192. doi: 10.1186/s13075-021-02549-0. Arthritis Res Ther. 2021. PMID: 34271991 Free PMC article.
We ranked treatments according to their effectiveness in preventing AU flare using the P-score. RESULTS: We identified 752 citations and included 33 RCTs, comprising 4544 treated patients (anti-TNF mAb 2101, etanercept [ETN] 699, anti-IL17A 1744) and 2497 placebo-re …
We ranked treatments according to their effectiveness in preventing AU flare using the P-score. RESULTS: We identified 752 citations …
A review of ocular adverse events of biological anti-TNF drugs.
Nicolela Susanna F, Pavesio C. Nicolela Susanna F, et al. J Ophthalmic Inflamm Infect. 2020 Apr 27;10(1):11. doi: 10.1186/s12348-020-00202-6. J Ophthalmic Inflamm Infect. 2020. PMID: 32337619 Free PMC article. Review.
The recent introduction of biological agents has revolutionized the treatment of chronic immune-inflammatory diseases; however, this new therapy did not come without significant side effects.Through large controlled studies indicating decrease in the number of uveitis f …
The recent introduction of biological agents has revolutionized the treatment of chronic immune-inflammatory diseases; however, this new the …
37 results